Literature DB >> 25008276

[Local drug therapy for inner ear hearing loss].

A Liebau1, S K Plontke.   

Abstract

The indications for local drug therapy of inner ear hearing loss include sudden sensorineural hearing loss, Menière's disease, autoimmune-associated hearing loss, ototoxicity as a side effect of other therapies, acute acoustic trauma and improvement of the safety and performance of cochlear implants. Various drugs are currently being used and tested for local treatment of inner ear hearing loss, including glucocorticoids, growth factors, apoptosis inhibitors, antioxidants, TNF-α inhibitors and antibodies. To further a better understanding of pharmacokinetics and the development of rational pharmacotherapy of the inner ear, the"liberation, absorption, distribution, metabolism, elimination" (LADME) principle can be applied to local therapy of the inner ear. Local application strategies can be differentiated into intratympanic applications to the middle ear cavity and direct intralabyrinthine or intracochlear applications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25008276     DOI: 10.1007/s00106-014-2890-9

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  35 in total

1.  Evaluation of the round window niche before local drug delivery to the inner ear using a new mini-otoscope.

Authors:  Stefan K Plontke
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

2.  Expression of p-glycoprotein is associated with that of multidrug resistance protein 1 (MRP1) in the vestibular labyrinth and endolymphatic sac of the guinea pig.

Authors:  T Saito; Z J Zhang; M Tokuriki; T Ohtsubo; I Noda; Y Shibamori; T Yamamoto; H Saito
Journal:  Neurosci Lett       Date:  2001-05-11       Impact factor: 3.046

Review 3.  State-of-the-art mechanisms of intracochlear drug delivery.

Authors:  David A Borkholder
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 2.064

4.  Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss.

Authors:  Saumil N Merchant; Joe C Adams; Joseph B Nadol
Journal:  Otol Neurotol       Date:  2005-03       Impact factor: 2.311

5.  Stimulation of free radical formation by aminoglycoside antibiotics.

Authors:  S H Sha; J Schacht
Journal:  Hear Res       Date:  1999-02       Impact factor: 3.208

6.  Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.

Authors:  F Van Wijk; H Staecker; E Keithley; P P Lefebvre
Journal:  Audiol Neurootol       Date:  2006-09-21       Impact factor: 1.854

7.  Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form.

Authors:  Christopher A Hargunani; J Beth Kempton; Jacqueline M DeGagne; Dennis R Trune
Journal:  Otol Neurotol       Date:  2006-06       Impact factor: 2.311

8.  Radial communication between the perilymphatic scalae of the cochlea. I: Estimation by tracer perfusion.

Authors:  A N Salt; K Ohyama; R Thalmann
Journal:  Hear Res       Date:  1991-11       Impact factor: 3.208

Review 9.  Inner ear drug delivery for auditory applications.

Authors:  Erin E Leary Swan; Mark J Mescher; William F Sewell; Sarah L Tao; Jeffrey T Borenstein
Journal:  Adv Drug Deliv Rev       Date:  2008-09-21       Impact factor: 15.470

10.  Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial.

Authors:  Takayuki Nakagawa; Tatsunori Sakamoto; Harukazu Hiraumi; Yayoi S Kikkawa; Norio Yamamoto; Kiyomi Hamaguchi; Kazuya Ono; Masaya Yamamoto; Yasuhiko Tabata; Satoshi Teramukai; Shiro Tanaka; Harue Tada; Rie Onodera; Atsushi Yonezawa; Ken-ichi Inui; Juichi Ito
Journal:  BMC Med       Date:  2010-11-25       Impact factor: 8.775

View more
  9 in total

1.  [Intratympanic injection therapy for therapy refractory acute hearing loss: A safe option for secondary treatment].

Authors:  G Mühlmeier; S Maier; M Maier; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

Review 2.  [Intracochlear drug delivery in combination with cochlear implants : Current aspects].

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

3.  [Reduction of permanent hearing loss by local glucocorticoid application : Guinea pigs with acute acoustic trauma. German version].

Authors:  M Müller; M Tisch; H Maier; H Löwenheim
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

4.  Reduction of permanent hearing loss by local glucocorticoid application : Guinea pigs with acute acoustic trauma.

Authors:  M Müller; M Tisch; H Maier; H Löwenheim
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

5.  Post-operative hearing among patients with labyrinthine fistula as a complication of cholesteatoma using "under water technique".

Authors:  K Thangavelu; R Weiß; J Mueller-Mazzotta; M Schulze; B A Stuck; K Reimann
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-09-20       Impact factor: 3.236

6.  [Multicenter trial for sudden hearing loss therapy - planning and concept].

Authors:  S K Plontke; M Girndt; C Meisner; R Probst; I Oerlecke; M Richter; J Steighardt; G Dreier; A Weber; I Baumann; S Plößl; J Löhler; R Laszig; J A Werner; T Rahne
Journal:  HNO       Date:  2016-04       Impact factor: 1.284

Review 7.  Intracochlear drug delivery in combination with cochlear implants : Current aspects.

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

Review 8.  Diagnostics and therapy of sudden hearing loss.

Authors:  Stefan K Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2018-02-19

9.  [Hormonal influence on hearing].

Authors:  J M Vahl; E Goldberg-Bockhorn; T K Hoffmann; M C Wigand
Journal:  HNO       Date:  2021-03-16       Impact factor: 1.284

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.